{{item.title}}
{{item.text}}
{{item.title}}
{{item.text}}
The healthcare market is experiencing a rapid and dynamic transformation, with artificial intelligence (AI) leading the charge. AI is revolutionizing the industry by creating a LIFEcare system that effortlessly incorporates prevention and personalized treatments into daily life. Building on our previous study, "Re-inventing Pharma with AI", this report explores the economic potential of AI in healthcare, offering strategic insights for pharmaceutical and life sciences companies. Based on a survey of more than 1,000 clients in the pharmaceutical and life sciences sectors, it provides regional and segment-specific guidance to capitalize on this substantial market opportunity.
This evolution will reshape care delivery, management, and experience. Predictive analytics will become commonplace, enabling proactive care by forecasting health outcomes. By 2030, AI could empower pharmaceutical companies to tap into a lucrative US$ 868 billion opportunity, leveraging innovative business models ranging from AI-driven trial management and precision medicine to cutting-edge consumer care platforms. In patient care, AI will enhance diagnostics and revolutionize remote monitoring and telemedicine, facilitating continuous care beyond traditional settings.
Our findings indicate significant growth in AI adoption within healthcare from 2025 to 2030. Currently, the share of the healthcare market addressed through AI accounts for less than 15% of the global healthcare market, but it is projected to exceed 30% by 2030. Adoption rates will vary by segment and region, reflecting different levels of AI development and focus.
Healthcare systems, regulatory frameworks, and technological infrastructures vary across geographic regions, necessitating market-specific, nuanced AI strategies.
To leverage AI's anticipated US$ 868 billion impact on healthcare by 2030, pharmaceutical companies must develop strategies that address regional differences and overcome existing challenges. Our survey shows that only 15% of organizations feel fully prepared to implement AI business models. While some companies have started integrating AI, most lack comprehensive strategies, struggling with scalability and expanding beyond internal efficiencies to realize commercial applications.
To boost AI adoption and develop commercially viable business models, pharmaceutical companies should adopt a hybrid approach that combines global strategy with regional execution:
Discover more about AI potentials, regional business models, and key takeaways for pharmaceutical and life sciences companies in our report, available for download as a PDF.
Johannes Dizinger, Jonathan Müller, Fabian Ahrens, Christelle Azar, Isabel Bayer, Florian Blaich, Niklas Klotz, Simon Gruber, and Lena Geier co-authored this report.